Zacks Small Cap Issues Positive Estimate for Azitra Earnings

Azitra, Inc. (NYSEAMERICAN:AZTR) – Zacks Small Cap upped their FY2025 earnings per share (EPS) estimates for shares of Azitra in a report released on Tuesday, November 18th. Zacks Small Cap analyst J. Vandermosten now anticipates that the company will post earnings per share of ($2.67) for the year, up from their previous forecast of ($3.41). The consensus estimate for Azitra’s current full-year earnings is ($2.78) per share. Zacks Small Cap also issued estimates for Azitra’s Q4 2025 earnings at ($0.37) EPS and FY2026 earnings at ($0.88) EPS.

Separately, Maxim Group reduced their price objective on shares of Azitra from $13.32 to $4.00 and set a “buy” rating for the company in a research note on Wednesday, September 24th. One equities research analyst has rated the stock with a Buy rating, According to MarketBeat, the company has a consensus rating of “Buy” and an average price target of $4.00.

Azitra Trading Down 3.2%

Shares of AZTR opened at $0.32 on Thursday. Azitra has a twelve month low of $0.30 and a twelve month high of $4.33. The business’s 50-day moving average price is $0.61 and its 200-day moving average price is $1.18.

Hedge Funds Weigh In On Azitra

A hedge fund recently raised its stake in Azitra stock. National Bank of Canada FI increased its position in Azitra, Inc. (NYSEAMERICAN:AZTR) by 175.0% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 110,000 shares of the company’s stock after buying an additional 70,000 shares during the quarter. National Bank of Canada FI owned 0.88% of Azitra worth $34,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 11.16% of the stock is currently owned by institutional investors and hedge funds.

Azitra Company Profile

Azitra, Inc, an early-stage biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It develops ATR-12, a genetically modified strain of S. epidermidis, which is in Phase Ib clinical trial for treating Netherton syndrome, a skin disease.